Wuxi apptec: the subsidiary cooperates with Hualing pharmaceutical for the commercial production of doglietine

AI Is Transforming China's Healthcare Industry

As AI gets more advanced, it is injecting vitality into traditional industries, allowing participants to picture very different futures to what they envisioned before.      

EqualOcean｜China's Top 20 ESG Performers Among Private Enterprises（Part III）

Private enterprises are actively embracing the transformative era

CRO ClinChoice Raises USD 150 Mn in Series E Round

2015 is the inflection point for the development of China's innovative drug industry and CRO (clinical research organization). On July 22nd, 2015, after CDE (Center For Drug Evaluation) released the announcement on self-examination and verification of drug clinical trial data, the supervision of Chinese clinical trials moved towards standardization. The investment and financing of innovative drugs in China continued to increase, laying the foundation for the growth of CRO.

Wuxi Apptec Embraces a More Health-Conscious China

After a booming year in 2018, Wuxi has yet to slow down. The following article analyzes the success of Wuxi and its shortcomings

Revenue and Net Profit of Wuxi Apptec Both Increased in 2020

Wuxi apptec said that the main reasons for the company's performance growth were the high growth of laboratories in China and the year-on-year growth of CDMO plate. China laboratory service is the core business of Wuxi apptec, accounting for more than 50% of its revenue. Its main business is small molecule drug discovery, drug analysis and testing.